Clinical Trials Logo

PTSD clinical trials

View clinical trials related to PTSD.

Filter by:

NCT ID: NCT04558112 Recruiting - PTSD Clinical Trials

Improving Therapeutic Learning for PTSD

Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

The proposed project seeks to demonstrate the engagement of post-exposure dopamine neurotransmission and downstream acute reorganization of dopaminergic resting-state neural networks as a means of increasing consolidation of extinction memories formed during analogue exposure therapy in adult women with PTSD. Participants will include 120 women aged 21-50 with a current diagnosis of PTSD related to physical or sexual assault, English speaking, and medically healthy. Participants will complete the stages of the study across 2-3 days, depending on participant need.

NCT ID: NCT04523922 Recruiting - Clinical trials for Alcohol Use Disorder

Oxytocin to Enhance Integrated Treatment for AUD and PTSD

COPE+OT
Start date: March 29, 2021
Phase: Phase 2
Study type: Interventional

The primary objective of the proposed Stage II study is to examine the efficacy of oxytocin (OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2) post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure). To evaluate purported neurobiological mechanisms of change, we will employ functional magnetic resonance imaging (fMRI) at pre- and post-treatment.

NCT ID: NCT04512755 Recruiting - Pain Clinical Trials

AIMS Medical Outcomes Study

AMOS
Start date: July 1, 2020
Phase:
Study type: Observational

This epidemiologic research is being conducted as an observational prospective case series outcomes study of the use of advanced integrative specialty medical care and its effect on adult and pediatric patients with chronic or serious illnesses or mental health disorders.

NCT ID: NCT04452500 Recruiting - PTSD Clinical Trials

Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)

SEVEN
Start date: October 15, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.

NCT ID: NCT04437498 Recruiting - PTSD Clinical Trials

Vagal Nerve Stimulation in mTBI

VNS mTBI
Start date: February 25, 2021
Phase: N/A
Study type: Interventional

Mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) are important conditions for the Veterans Administration (VA) that frequently occur together in combat Veterans from the conflicts in Afghanistan and Iraq. In many Veterans these become chronic, raising the risk the burden of neurotrauma can worsen over time. This study will examine a new intervention called non-invasive Vagal Nerve Stimulation (nVNS) and its effects on memory and symptoms of PTSD and mTBI as well as brain and physiology in Veterans with mTBI and PTSD.

NCT ID: NCT04437095 Recruiting - Depression Clinical Trials

Positive Suggestions Via MP3 Messages

Start date: August 17, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the use of an audio recording containing positive suggestion as a means to provide needed psychological support to critically ill patients in a feasible and reliable manner.

NCT ID: NCT04421573 Recruiting - PTSD Clinical Trials

Cervical Plexus Hydrodissection With D5W for PTSD

Start date: July 10, 2023
Phase: N/A
Study type: Interventional

PTSD is a chronic mental health condition that drastically reduces an individual's quality of life Dextrose injection with a small needle has been used for chronic pain patients and observational results have shown it to be effective in reducing anxiety, brain fog, and depression in patients with PTSD. This randomized trial will compare dextrose injection with a delayed/usual treatment control.

NCT ID: NCT04418778 Recruiting - PTSD Clinical Trials

The BEAR Therapeutic Program for Women

Start date: March 1, 2023
Phase:
Study type: Observational

The current study aims to test a novel therapeutic intervention for women who have a history of interpersonal trauma. The Building Empowerment and Resilience (BEAR) Therapeutic group incorporates psychological skills, psychoeducation, and physical empowerment training, all within a therapeutic process. It will be implemented iwith women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect). The investigators aim to understand how this program effects one's self-efficacy and whether the program can reduce rates mental health problems (such as depression and anxiety) and reduce the rates of revictimization. Women who participate in the BEAR group must be able to attend in-person sessions. The control group can be remote.

NCT ID: NCT04317820 Recruiting - PTSD Clinical Trials

Deep Brain Reorienting in Post-traumatic Stress Disorder

Start date: September 29, 2020
Phase: N/A
Study type: Interventional

This study will evaluate the efficacy of a therapeutic treatment, Deep Brain Reorienting (DBR), for PTSD (Post-traumatic Stress Disorder). Participants will be randomized to either the DBR treatment, or wait-list condition.

NCT ID: NCT04228289 Recruiting - PTSD Clinical Trials

Oxytocin to Treat PTSD

Start date: November 16, 2020
Phase: Phase 2
Study type: Interventional

Posttraumatic stress disorder (PTSD) is a chronic, debilitating condition that disproportionately affects Veterans. Prolonged Exposure (PE) therapy is a "gold standard" treatment for PTSD. However, approximately one-third of Veterans fail to receive an adequate dose of treatment because they prematurely drop out of PE therapy. There is also room to improve PE treatment outcomes. Consistent with the VA Office of Research and Development initiative to develop effective treatments for PTSD, the proposed randomized clinical trial will examine the ability of oxytocin (as compared with placebo) combined with PE to reduce PTSD symptom severity, improve the rate of PTSD symptom reduction, and to enhance PE treatment retention and adherence. This two-site study will leverage the investments made in the nationwide rollout off PE therapy and has the potential to significantly improve mental health care among Veterans, advance the science in this area, and identify mechanisms underlying positive PTSD treatment response. Participants may choose to complete this research study via home-based telemedicine (HBT) care (i.e. service delivery to patients in their homes using consumer friendly, video-conferencing technology). HBT sessions will be delivered via standard desk, laptop computer, tablet, or smartphone using VA approved applications. All procedures that take place via telemedicine will be performed and completed as though they were in-person/in-office